Search the Newsreel

The Bull Case For Heartland Express (HTLD) Could Change Following Analyst Upgrades And Momentum Shift – Learn Why

Heartland Express (HTLD) has recently received a top-tier Momentum Style Score of A and a Zacks Rank of #2, indicating strong analyst confidence and upgraded earnings estimates. This improved outlook suggests analysts are becoming more optimistic about the company's ability to return to profitability …

Artelo Biosciences grants options to director | ARTL Insider Trading

Artelo Biosciences director Robert Martin received a grant of 136 stock options with an exercise price of $1.15 per share, expiring on July 17, 2036. The options will vest 100% on the earlier of one year from July 17, 2026, or the day before …

Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney

Artelo Biosciences (ARTL) has granted its director, Douglas Blayney, stock options for 136 shares of common stock. The options have an exercise price of $1.15 per share and will expire on July 17, 2036. The shares are set to vest 100% on the earlier …

Artelo Biosciences (ARTL) Proxy filing Summary

Artelo Biosciences (ARTL) has released a proxy filing summary detailing voting matters for its upcoming annual meeting. Shareholders are asked to elect three directors—Gregory R. Reyes, Tamara A. Favorito, and Gregory D. Gorgas—and to approve an amendment to increase authorized common stock from 166,666,667 …

Heartland Express (HTLD) Is Up 3.99% in One Week: What You Should Know

Heartland Express stock trades steady as integration costs weigh on margins

Heartland Express (HTLD) stock is trading steady as the company navigates the integration of recent acquisitions, which has led to higher operating costs and weighed on margins in fiscal year 2024. Despite a 14% increase in revenue to $690 million, profitability has been impacted …

Is Heartland Express (HTLD) Expensive As Sales And Earnings Stay Under Pressure?

Heartland Express (HTLD) is under investor scrutiny due to declining sales and earnings, despite a significant recent share price increase. While its Price-to-Sales ratio suggests overvaluation compared to its fair value and industry average, a Discounted Cash Flow model indicates the stock might be …

Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies

Artelo Biosciences, Inc. (NASDAQ: ARTL) reported the results of its Annual Meeting of Stockholders held on July 17, 2026. Stockholders voted on the re-election of three Class III directors and approved two other proposals, including an increase in authorized common stock and a share …

Artelo Biosciences (ARTL) AGM 2026 Summary

Artelo Biosciences (ARTL) held its 2026 Annual General Meeting, where shareholders considered several key proposals. These included the re-election of three Class III directors, an amendment to increase the authorized common stock from 166,666,667 to 500 million, and approval for issuing over 20% of …

ARTL: All proposals, including director elections and share increases, were approved

Artelo Biosciences, Inc. (ARTL) shareholders approved all proposals during their 2026 AGM, including director elections, an increase in authorized shares, and a major equity issuance. No shareholder questions were raised during the Q&A session. This information is based on the company's AGM 2026 Audio …

Artelo presents preclinical data on osteoarthritis pain drug

Artelo Biosciences announced preclinical study results for ART26.12, its osteoarthritis pain drug, showing it reduced pain behaviors in studies and had comparable efficacy to naproxen with fewer side effects. The company plans to start a clinical study in Q4 to evaluate its safety and …

Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions

Artelo Biosciences announced positive nonclinical study results for ART26.12, its FABP5 inhibitor, showing its potential as a first-in-class treatment for osteoarthritis pain. The drug demonstrated efficacy comparable to naproxen in reducing pain, while significantly minimizing gastrointestinal tissue damage, suggesting a safer profile than traditional …

The Technical Signals Behind (HTLD) That Institutions Follow

Quantitative Research Desk provides a technical analysis of Heartland Express Inc. (NASDAQ: HTLD), indicating a neutral sentiment in the near and mid-term, with a strong long-term positive bias. The analysis highlights a 35.0:1 risk-reward short setup and offers three distinct trading strategies (Position, Momentum …

Heartland Express (HTLD) Projected to Announce Earnings on Thursday

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Artelo Biosciences is reminding its shareholders to vote their shares before its Annual Meeting on July 17, 2026. The company emphasizes that submitting a proxy is crucial for establishing the necessary quorum, regardless of how shareholders choose to vote. This participation ensures the company …

Euroz Hartleys Group (ASX:EZL): Why This Stockbroking Deal Could Reshape an ASX Small-Cap Name

ASX Penny Stocks Spotlight: Euroz Hartleys Group Among 3 Promising Picks

Australian Shares Down; Euroz Hartleys Group Agrees to Sell Capital Markets Business to BMO Australia

Euroz Hartleys (ASX:EZL) Shares Gain Following Strategic Business Reshaping

Bank of Montreal Eyes Euroz Hartleys in Potential Stockbroking Takeover

Bank Of Montreal Weighs Euroz Hartleys Deal And Valuation Trade Offs

Heartland Group Announces Conditional Merger of Heartland Bank and TSB

Heartland Group (ASX:HGH) Up Over 11% on Merger Day: What TSB Deal Costs and What It Buys

Proposed Merger Of Heartland Bank And TSB Will Create A New Zealand Challenger Bank Of Scale With A Regional Focus - Scoop

Heartland Bank planning to buy TSB for $620 million in merger

Banking shake-up: Heartland to buy TSB for $620m in proposed full-service merger

Q1 Ground Transportation Earnings Review: First Prize Goes to Heartland Express (NASDAQ:HTLD)

Smartlink Holdings FY26 Net Profit Surges; Dividend and Key Appointments Approved

Smartlink Net Consolidated March 2026 Net Sales at Rs 99.35 crore, up 51.84% Y-o-Y

Smartlink Holdings Schedules Board Meeting on May 13, 2026 for FY26 Financial Results Approval

Bhagwan Marine Disappoints Market With Core Business Earnings Miss, Euroz Hartleys Says

Can Heartland Express (HTLD) Run Higher on Rising Earnings Estimates?

Heartland Express (HTLD) Releases Q1 2026 Earnings: Revenue and EPS Drop, Operating Cash Flow Surges

Is Heartland Express (HTLD) Outperforming Other Transportation Stocks This Year?

A Look At Heartland Express (HTLD) Valuation After Q1 Results Narrowed Losses But Sales Declined

Heartland Express (HTLD) Stock Trades Up, Here Is Why